首页> 外文期刊>The Journal of Immunology: Official Journal of the American Association of Immunologists >Laser-Assisted Intradermal Delivery of Adjuvant-Free Vaccines Targeting XCR1(+) Dendritic Cells Induces Potent Antitumoral Responses
【24h】

Laser-Assisted Intradermal Delivery of Adjuvant-Free Vaccines Targeting XCR1(+) Dendritic Cells Induces Potent Antitumoral Responses

机译:激光辅助靶向XCR1(+)树突状细胞的无佐剂疫苗皮内传递诱导有效的抗肿瘤反应。

获取原文
获取原文并翻译 | 示例
           

摘要

The development of vaccines inducing efficient CD8(+) T cell responses is the focus of intense research. Dendritic cells (DCs) expressing the XCR1 chemokine receptor, also known as CD103(+) or CD8 alpha(+) DCs, excel in the presentation of extracellular Ags to CD8(+) T cells. Because of its high numbers of DCs, including XCR1(+)DCs, the skin dermis is an attractive site for vaccine administration. By creating laser-generated micropores through the epidermis, we targeted a model protein Ag fused to XCL1, the ligand of XCR1, to dermal XCR1(+) DCs and induced Ag-specific CD8(+) and CD4(+) T cell responses. Efficient immunization required the emigration of XCR1(+) dermal DCs to draining lymph nodes and occurred irrespective of TLR signaling. Moreover, a single intradermal immunization protected mice against melanoma tumor growth in prophylactic and therapeutic settings, in the absence of exogenous adjuvant. The mild inflammatory milieu created in the dermis by skin laser microporation itself most likely favored the development of potent T cell responses in the absence of exogenous adjuvants. The existence of functionally equivalent XCR1(+) dermal DCs in humans should permit the translation of laser-assisted intradermal delivery of a tumor-specific vaccine targeting XCR1(+) DCs to human cancer immunotherapy. Moreover, considering that the use of adjuvants in vaccines is often associated with safety issues, the possibility of inducing protective responses against melanoma tumor growth independently of the administration of exogenous adjuvants should facilitate the development of safer vaccines.
机译:诱导有效CD8(+)T细胞反应的疫苗的开发是广泛研究的重点。表达XCR1趋化因子受体的树突状细胞(DC),也称为CD103(+)或CD8 alpha(+)DC,在将胞外Ag呈递给CD8(+)T细胞方面表现出色。由于皮肤DC数量很高,包括XCR1(+)DC,因此皮肤真皮是疫苗接种的诱人场所。通过创建通过表皮的激光产生的微孔,我们将与XCL1(XCR1的配体)融合的模型蛋白Ag靶向皮肤XCR1(+)DC,并诱导Ag特异性CD8(+)和CD4(+)T细胞反应。有效的免疫接种要求XCR1(+)真皮DC迁移至引流淋巴结,并且无论TLR信号传导如何均会发生。此外,在没有外源佐剂的情况下,单次皮内免疫可以在预防和治疗环境中保护小鼠免受黑素瘤肿瘤的生长。在没有外源性佐剂的情况下,皮肤激光微穿孔本身在真皮中产生的轻度炎性环境最有可能促进有效的T细胞反应的发展。在人类中功能上等效的XCR1(+)真皮DC的存在应允许将针对XCR1(+)DC的肿瘤特异性疫苗的激光辅助皮内递送翻译为人类癌症免疫疗法。此外,考虑到佐剂在疫苗中的使用通常与安全性问题有关,独立于外源佐剂的给药而诱导针对黑素瘤肿瘤生长的保护性反应的可能性应有助于开发更安全的疫苗。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号